吡格列酮诱导实验性糖尿病大鼠膀胱尿路上皮发育异常改变。
Pioglitazone Induces Dysplastic Urothelial Changes in Urinary Bladder of Experimental Diabetes.
作者信息
Abdel-Hamid Ahmed A M, Firgany Alaa El-Din L
机构信息
Department of Anatomy, Taibah College of Medicine, Taibah University, Almadina Almonawara, Buraydah, Kingdom of Saudi Arabia.
Department of Histology and Medical Cell Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
出版信息
J Microsc Ultrastruct. 2021 Aug 6;11(1):34-40. doi: 10.4103/jmau.jmau_34_21. eCollection 2023 Jan-Mar.
OBJECTIVES
Pioglitazone (PIO) is a widely prescribed oral antidiabetic drug that has concerns regarding a potential risk of developing carcinoma of the urinary bladder. The objective of the current study was to assess this potential risk.
MATERIALS AND METHODS
The potential risk of PIO-induced urinary bladder carcinoma was assessed in the current study by examining urinary bladder of rats for urothelial cytokeratin (CK) expression and proliferative activity by Ki67 immunostaining.
RESULTS
Histological examination revealed dysplastic urothelial changes in PIO and diabetes mellitus + PIO (diabetic rats receiving PIO). In addition, a significantly ( < 0.05) decreased CK7 and CK8 expression together with a significantly increased CK20 as well as Ki67 expression was detected in the urothelial cells of groups administrated PIO, contrary to those which did not.
CONCLUSION
The manifestations of urothelial dysplasia evidenced by histological examination as well as by the aberrant expression in CK and Ki67 after PIO administration add supporting evidence at cellular and experimental level to the previous clinical suspicions.
目的
吡格列酮（PIO）是一种广泛使用的口服抗糖尿病药物，人们担心其有患膀胱癌的潜在风险。本研究的目的是评估这种潜在风险。
材料与方法
在本研究中，通过对大鼠膀胱进行尿路上皮细胞角蛋白（CK）表达检测以及用Ki67免疫染色检测增殖活性，来评估PIO诱发膀胱癌的潜在风险。
结果
组织学检查显示，在PIO组以及糖尿病 + PIO组（接受PIO的糖尿病大鼠）中出现了发育异常的尿路上皮变化。此外，与未给药组相比，给药组尿路上皮细胞中CK7和CK8表达显著降低（<0.05），而CK20以及Ki67表达显著增加。
结论
组织学检查以及PIO给药后CK和Ki67的异常表达所证明的尿路上皮发育异常表现，在细胞和实验水平上为先前的临床怀疑增添了支持证据。
Zotero 插件